Bioverativ Inc.

Bioverativ Inc. is a biopharmaceutical company that engages in the development of therapies and programs for hemophilia, cold agglutinin disease, sickle cell disease, beta thalassemia, and other blood disorders. Its pipeline includes hemophilia programs that provide less-frequent prophylactic dosing for hemophilia A and subcutaneous dosing for hemophilia B; and gene therapy programs for hemophilia A and B. The company also includes programs to address cold agglutinin disease, a rare and chronic autoimmune hemolytic condition; and Sutimlimab (formerly BIVV009), a therapy in development that is designed to selectively inhibit the complement pathway of the immune system. Bioverativ Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. Bioverativ Inc. operates as a subsidiary of Sanofi.